These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 126059)

  • 1. Neocarzinostatin: a new agent active in the treatment of acute leukemia.
    Kitajima K; Kamimura O; Nagao T; Takahashi I; Hiraki K
    Bibl Haematol; 1975; (40):751-2. PubMed ID: 126059
    [No Abstract]   [Full Text] [Related]  

  • 2. Mode of decrease of leukemic cells and leukocytes during neocarzinostatin treatment.
    Masaoka T; Hasegawa Y; Yoshitake J; Ueda T; Takubo T
    Cancer Treat Rep; 1977; 61(1):73-5. PubMed ID: 140763
    [No Abstract]   [Full Text] [Related]  

  • 3. [The clinical evaluation of a new antileukemic agent. 2) Neocarzinostatin (author's transl)].
    Kitajima K
    Nihon Ketsueki Gakkai Zasshi; 1974 Oct; 37(5):767-72. PubMed ID: 4282818
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase I study of neocarzinostatin in patients with acute leukemia.
    Van Echo DA; Wiernik PH
    Cancer Treat Rep; 1978 Sep; 62(9):1363-5. PubMed ID: 150945
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of acute leukemia with neocarzinostatin (NCS)].
    Masaoka T; Nakamura H; Hasegawa Y; Shibata H; Tatsumi N
    Rinsho Ketsueki; 1974 Dec; 15(12):1309-16. PubMed ID: 4282747
    [No Abstract]   [Full Text] [Related]  

  • 6. Zinostatin (neocarzinostatin).
    Issell BF; Prestayko AW; Comis RL; Crooke ST
    Cancer Treat Rev; 1979 Dec; 6(4):239-49. PubMed ID: 161199
    [No Abstract]   [Full Text] [Related]  

  • 7. Neocarzinostatin: report of a phase II clinical trial.
    McKelvey EM; Murphy W; Zander A; Bodey GP
    Cancer Treat Rep; 1981; 65(7-8):699-701. PubMed ID: 6454486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of acute nonlymphocytic leukemia with neocarzinostatin.
    Griffin TW; Lister TA; Rybak ME; Rosenthal DS; Canellos GP; Woodruff R; Oliver KT
    Cancer Treat Rep; 1979; 63(11-12):1853-6. PubMed ID: 160835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical investigations of neocarzinostatin in Japan.
    Kimura I
    Recent Results Cancer Res; 1978; 63():252-60. PubMed ID: 151899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The induction chemotherapy of acute leukemia with a new antileukemic agent "neocarzinostatin" (author's transl)].
    Nagao T; Kamimura O; Takahashi I; Kitajima K; Hiraki K
    Rinsho Ketsueki; 1973 Sep; 14(9):925-30. PubMed ID: 4797130
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II trial of zinostatin in children with late-stage acute lymphocytic leukemia: a Pediatric Oncology Group Study.
    Sexauer C; Kim T; Nix W; Berry DH; Morgan S
    Cancer Treat Rep; 1981; 65(1-2):173-4. PubMed ID: 6452947
    [No Abstract]   [Full Text] [Related]  

  • 12. Caffeine potentiation on lethality of L-1210 cells treated with neocarzinostatin.
    Sasada M; Sawada H; Nakamura T; Uchino H
    Gan; 1976 Jun; 67(3):447-9. PubMed ID: 137161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neocarzinostatin in cancer chemotherapy (review).
    Maeda H
    Anticancer Res; 1981; 1(3):175-86. PubMed ID: 6211130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The treatment of pancreatic carcinoma with neocarzinostatin].
    Kinami Y; Miyazaki H; Koyama F; Noguchi M; Konishi K
    Nihon Gan Chiryo Gakkai Shi; 1975 Dec; 10(4):502-8. PubMed ID: 130432
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of malignant glioma with neocarzinostatin. A combined chemoradiotherapy with intra-arterial neocarzinostatin perfusion and irradiation].
    Uemura S; Matsukado Y; Sonoda H; Kuratsu J; Ohtsuka T; Yoshioka S; Yoshida A; Kochi M; Marubayashi T
    Neurol Med Chir (Tokyo); 1986 Apr; 26(4):304-10. PubMed ID: 2429207
    [No Abstract]   [Full Text] [Related]  

  • 16. Prophylactic effects of perioperatively administered neocarzinostatin in renal cell carcinoma.
    Satake I; Tari K; Ohwada F; Saitoh T; Negishi T
    Nihon Gan Chiryo Gakkai Shi; 1989 Apr; 24(4):809-16. PubMed ID: 2528598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of systemic administration of neocarzinostatin, a new protein antibiotic, on human bladder cancer.
    Sakamoto S; Ogata J; Ikegami K; Maeda H
    Cancer Treat Rep; 1978 Mar; 62(3):453-4. PubMed ID: 148320
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemotherapy for bladder cancer with neocarzinostatin: evaluation of systemic administration.
    Sakamoto S; Ogata J; Ikegami K; Maeda H
    Eur J Cancer (1965); 1980 Jan; 16(1):103-13. PubMed ID: 6444585
    [No Abstract]   [Full Text] [Related]  

  • 19. Neocarzinostatin: a phase I clinical trial with five-day intermittent and continuous infusions.
    McKelvey EM; Burgess MA; McCredie KB; Murphy WK; Bodey GP
    Cancer; 1979 Oct; 44(4):1182-8. PubMed ID: 159119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neocarzinostatin: initial clinical and pharmacologic studies in the United States.
    Comis RL; Griffin T; Raso V; Ginsberg SJ
    Recent Results Cancer Res; 1978; 63():261-71. PubMed ID: 151900
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.